Chronic Constipation, Methanogenesis Clinical Trial
Official title:
Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation
Lubiprostone, a chloride channel activator, has been shown to improve symptoms of chronic
constipation, largely by enhancing chloride-rich intestinal fluid secretion. Whether
Lubiprostone has effects on colonic methanogenesis is not known. The investigators
hypothesize that the effects of Lubiprostone may in part be due to its effects on altering
colonic flora, particularly methanogenic flora.
By altering the colonic stasis of stool and through more efficient clearance of digestive
residue, the investigators anticipate that Lubiprostone may either inhibit or promote better
excretion of methanogenic flora, and thereby decrease the gut load of methane producing
bacteria. In turn, this may lead to enhanced colonic smooth muscle contraction and an
increased rate of spontaneous bowel movements and reduction of constipation symptoms.
The aim is to investigate the effects of Lubiprostone on intestinal methane production and
bowel symptoms in patients with chronic constipation, by performing a randomized, double
blind, placebo controlled study.
n/a